Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 62170 record(s)

Req # A-2023-000983

Current standing/ stop sale requests for ELEVAI EXOSOMES distributed by Evolve Medical.

Organization: Health Canada

106 page(s)
February 2024

Req # A-2023-001021

The Section 1.0.7 “Note to the Reviewer” from the generic manufacturer of the Liraglutide Abbreviated New Drug Submission (ANDS) which appears on the Generic Submissions Under Review (GSUR) List.

Organization: Health Canada

16 page(s)
February 2024

Req # A-2023-001028

All correspondence or other records relating to any pre-submission or pre-application meeting(s) requested by a sponsor in respect of a drug submission/application for a product containing the medicinal ingredient semaglutide.

Organization: Health Canada

23 page(s)
February 2024

Req # A-2023-001029

All correspondence in respect of the liraglutide submission which was removed from the Generic Submissions Under Review (GSUR) List some time between March 15, 2022 and December 13, 2022 between Health Canada and the company (sponsor) who submitted the Abbreviated New Drug Submission (ANDS).

Organization: Health Canada

104 page(s)
February 2024

Req # A-2023-001047

A Health Canada Compliance and Enforcement Inspection Report on the Cannabis Industry reported, for 2018-19, 32 referrals from Health Canada to the Royal Canadian Mounted Police (RCMP) for action. The names of the 32 companies and/or promotions events that were referred to the RCMP; Reasons for the referrals to the RCMP; Dates of the 32 referrals to the RCMP and identification of which RCMP detachments the referral went to; Correspondence between Health Canada and RCMP related to these referrals; Current status or outcomes of the referrals to the RCMP, if the RCMP has already communicated these to Health Canada.

Organization: Health Canada

74 page(s)
February 2024

Req # A-2023-001083

Information regarding product name, dosage form and strength of Carbidopa, levodopa generic submissions under review. This product listed under Generic Submissions Under Review list dated 2023-10-19.

Organization: Health Canada

3 page(s)
February 2024

Req # A-2023-001153

A report/speadsheet showing the total number of consultant hired and all corresponding costs, broken down by department/agency and calendar year (2015 - 2023).

Organization: Health Canada

3 page(s)
February 2024

Req # A-2023-001158

All information included in the submission and review of Natural Product Number (NPN) 80059723 Berberine/Berberine 500 mg.

Organization: Health Canada

54 page(s)
February 2024

Req # A-2023-001188

A line listing in the Canada Vigilance Database of adverse reaction reports involving "copycat" edible cannabis products. Case reports made between the dates 01/01/2017 - 12/19/2023

Organization: Health Canada

7 page(s)
February 2024

Req # A-2023-001203

Research/studies Health Canada uses to base the decisions on warning Canadians for pregabalin/Lyrica.

Organization: Health Canada

254 page(s)
February 2024
Date modified: